SCM
INFI

Sigma Capital Management’s Infinity Pharmaceuticals, Inc. INFI Stock Holding History

Sigma Capital Management’s Portfolio INFI Stock Details INFI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-50,000
Closed -$691K – 216
2013
Q4 		$691K Buy
+50,000
New +$706K 0.04% 146

Other funds holding INFI

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
SCA
SAC Capital Advisors Stamford, Connecticut $19.3B AUM 31.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Sigma Capital Management's INFI Position: Q1 2014 in Review

Sigma Capital Management sold out of Infinity Pharmaceuticals, Inc. (INFI) in Q1 2014, closing a stake of 50,000 shares — an estimated $691K sold.

Sigma Capital Management first reported a position in INFI in Q4 2013 and held it in 1 quarter. The position peaked at $691K in Q4 2013. 98 funds tracked by Wall St. Rank hold INFI as of Q1 2014.

  • Sigma Capital Management reported no remaining Infinity Pharmaceuticals, Inc. position as of Q1 2014 after selling out during the quarter.
  • Sigma Capital Management sold 50,000 Infinity Pharmaceuticals, Inc. shares in Q1 2014, an estimated $691K.
  • Sigma Capital Management first reported a position in Infinity Pharmaceuticals, Inc. in Q4 2013 and held it in 1 quarter.
  • Sigma Capital Management's Infinity Pharmaceuticals, Inc. position peaked at $691K in Q4 2013.
  • 98 funds tracked by Wall St. Rank held Infinity Pharmaceuticals, Inc. as of Q1 2014.

Based on Sigma Capital Management's 13F filing for Q1 2014, filed 15 May 2014.